OVARIAN CANCER TYPE I TYPE II ADVANCED NON ADVANCED
  ALL PM M ALL PM M ALL PM M ALL PM M
SENSITIVITY
[%]
ROMA 78.9 60 85.7 95.6 90.9 97.1 96.7 91.7 98 63.6 55.6 69.2
ROMA1 76.3 60 82.1 93.3 90.9 94.1 95.1 91.7 95.9 59.1 55.6 61.5
HE4 65.8 50 71.4 91.1 90.9 91.2 90.2 91.7 89.8 52.4 44.4 53.8
CA125 86.8 70 92.9 93.3 100 91.2 96.7 100 95.9 72.7 66.7 76.9
SPECIFICITY
[%]
ROMA 88.5 91.6 80.6 88.5 81.8 80.6 88.5 91.6 80.6 88.5 91.6 80.6
ROMA1 95.4 96.8 91.7 95.4 96.8 91.7 95.4 96.8 91.7 95.4 96.8 91.7
HE4 87.8 89.5 83.3 87.8 89.5 83.3 87.8 89.5 83.3 87.8 89.5 83.3
CA125 72.5 71.6 75 72.5 71.6 75 72.5 71.6 75 72.5 71.6 75
PPV
 [%]
ROMA 66.7 42.9 77.4 74.1 55.6 82.5 79.7 64.7 87.3 48.3 38.5 56.3
ROMA1 82.9 66.7 88.5 87.5 76.9 91.4 90.7 78.6 94 68.4 62.5 72.7
HE4 61 33.3 76.9 72 50 83.8 77.5 52.4 88 40.7 28.6 53.8
CA125 52.2 20.6 74.3 53.8 28.9 77.5 37.9 30.8 83.9 30.8 18.2 52.6
NPV
[%]
ROMA 93.5 95.6 87.9 98.3 98.9 96.7 98.3 98.9 96.7 93.5 95.6 87.9
ROMA1 93.3 95.8 86.8 97.7 98.9 94.3 97.7 98.9 94.3 93.3 95.8 86.8
HE4 89.9 50 78.9 96.6 91 90.9 95 98.8 85.7 52.4 94.4 83.3
CA125 74.2 95.8 93.1 96.9 100 90 97.9 100 93.1 94.1 95.8 90
All – PM+M; PM – Premenopause; M – Postmenopause ; ROMA 1 – risk stratification based on cutoff points determined by authors
Table 4: Sensitivity, specificity, PPV, and NPV of CA125, HE4, and ROMA for identification of type and stage of ovarian cancer.